Influx Healthtech IPO Details
Influx Healthtech IPO Summary
Influx Healthtech IPO opens for subscription on 18 Jun 2025 and closes on 20 Jun 2025.The IPO will be listed on NSE with the tentative listing date set for 25 Jun 2025.
Influx Healthtech IPO price band has been fixed at ₹91 – ₹96 per share. The face value is ₹10 per share with a lot size of 1200.
Influx Healthtech IPO total issue size comprises 61,00,800 shares (aggregating up to ₹58.57 Cr). This includes a fresh issue of 50,00,400 shares (aggregating up to ₹48.00 Cr). Offer for Sale consists of 11,00,400 shares (aggregating up to ₹10.56 Cr). Pre-issue shareholding stands at 1,81,50,000, which will increase to 2,31,50,400 post-issue.
Influx Healthtech IPO carries a ₹20 (20.83%) GMP, reflecting investor sentiment.
Influx Healthtech IPO Lot Size :Retail Minimum is 1 lot (1,200 shares) amounting to ₹115,200. Retail Maximum is 1 lot (1,200 shares) amounting to ₹115,200. SHNI Minimum is 2 lots (2,400 shares) amounting to ₹230,400.
The Lead Managers for Influx Healthtech IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Rarever Financial Advisors Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is R.K.Stock Holding. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Influx Healthtech Limited RHP.
Influx Healthtech IPO Details
Influx Healthtech IPO Subscription
Influx Healthtech IPO Application Wise Breakup
Influx Healthtech IPO Dates
- 18 Jun 2025Opening dateOpen
- 20 Jun 2025Closing dateClose
- 23 Jun 2025Allotment Date Allotment
- 24 Jun 2025Initiation of RefundsRefund
- 24 Jun 2025Credit of SharesCredit
- 25 Jun 2025Listing dateListing
Influx Healthtech IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 1200 | ₹115,200 |
| Retail Maximum | 1 | 1200 | ₹115,200 |
| SHNI Minimum | 2 | 2400 | ₹230,400 |
| SHNI Maximum | 0 | 0 | ₹ |
| BHNI Minimum | 0 | 0 | ₹ |
Influx Healthtech IPO Reservation
Promoter Holding
Documents
Influx Healthtech IPO Valuations
Influx Healthtech Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 70.30 | 41.10 | 28.30 |
| Revenue | 104.99 | 100.10 | 76.07 |
| Profit After Tax | 13.37 | 11.22 | 7.20 |
| Net Worth | 36.15 | 22.87 | 11.65 |
| Reserves and Surplus | 18.00 | 22.85 | 11.63 |
| Total Borrowing | 0.22 | 0.32 | 0.80 |
| Amount in ₹ Crore | |||
About Influx Healthtech IPO
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing. The company is a reliable CDMO, providing specialized services to clients in multiple industries.
The company has three manufacturing facilities in Thane, Maharashtra, each covering an area of 9,676 square feet, 13,000 square feet, and 14,000 square feet, respectively.
Product Portfolio:
- Tablets, Capsules, and Powders
- Liquid Orals and Softgels
- Lozenges, Jellies, and Gummies
- Oral Dispersible Films (ODFs)
- Effervescent Tablets and Liquid-Fill Capsules
- Candies and Gym/Sports Supplements
- Skin Care and Body Care Products
- Hair Care and Beard Care Solutions
- Face Masks and Soaps.
- Ayurvedic / Herbal formulations
- Veterinary Feed Supplements
- Homecare solutions
The Company aids Nutraceutical and Cosmetic firms with product development and manufacturing. It offers end-to-end services, including development, production, and regulatory support, enabling clients to focus on formulation and commercialization.
As of June 11, 2025, the company has 163 permanent employees on a payroll basis.
Strength Of Influx Healthtech IPO
1. Diverse client base with longstanding CDMO relationships.
2. Well versed and equipped advanced manufacturing facilities with global accreditations.
3. Large and rapidly growing R&D capabilities across our product portfolio.
4. Experienced Promoter and management team with strong industry expertise and successful track record.
5. Robust Quality Assurance & Control practices.
6. Proven Track record of growth and profitability.
Risk Of Influx Healthtech IPO
1. The Company is reliant on the demand from the nutraceutical industry for a significant portion of its revenue. Any downturn in the nutraceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.
2. Its existing manufacturing facility are concentrated in a single region i.e., Palghar, Thane, Maharashtra and the inability to operate and grow its business in this particular region may have an adverse effect on its business, financial condition, results of operations, cash flows and future business prospects.
3. The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect its revenues and profitability.
4. The company has historically derived, and may continue to derive, a signification of its supply from top 10 Suppliers. Also, the Company has not entered into long-term agreements with these suppliers. In the event the company is unable to procure adequate amounts of raw materials, at competitive prices its business, results of operations and financial condition may be adversely affected.
5. Too much Geographical concentration of its Business on specific location can impact the company Business.
6. Its reliance on certain industries for a significant portion of its sales could have an adverse effect on its business.
7. The company has not taken any steps to order the machinery/equipment required for the proposed expansion. In the event of any delay in placing the orders, or in the event the vendors are not able to provide the equipment / machineries in a timely manner, or at all, the same may result in time and cost over-runs.
8. Its business activities are exposed to fluctuations in the prices of raw materials.
9. Its may face several risks associated with the construction of the building of the Proposed Expansion, which could hamper its growth, prospects, cash flows and business and financial condition.
10. Its Registered Office, Factory Units and Godown is located on premises which are not owned by it and has been obtained on license basis from the promoters of the company. Disruption of its rights as licensee/ lessee or termination of the agreements with its licensors/ lessors (promoters) may adversely impact its operations and, consequently, its business, financial condition and results of operations.
Objectives Influx Healthtech IPO
1. Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division
2. Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division
3. Purchase of Machineries for Homecare and Cosmetic Division
4. General corporate purposes
Company Contact Details
Influx Healthtech Limited
109, Ghanshyam Enclave Premises Co-op
Soc Plot No. 856, Laljipada
Kandivali West,
Mumbai, Maharashtra
Phone: +91 7045997809
Email: cs@influxhealthtech.com
Website: https://influxhealthtech.com/
Registrar Contact Details
Influx Healthtech FAQs
The Influx Healthtech IPO is a SME public issue comprising 6100800 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹58.57 Cr. The issue price has been fixed at ₹96 per equity share, and the minimum application size is 1200 shares.
The IPO opens for subscription on 18 Jun 2025, and closes on 20 Jun 2025.
Maashitla Securities Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the NSE
As of now, the current GMP stands at ₹20 (20.83%).
Quick Links
Comments
